Patient Focused Treatment Decisions in Metastatic
Colorectal Cancer (mCRC): A Closer Look at the
Role of Biomarkers in Optimizing Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Fall Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from March 10, 2018 to March 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Bayer HealthCare Pharmaceuticals, Lilly USA LLC, and Taiho Oncology

Colorectal cancer (CRC) is the development of cancer from the colon or rectum and has the ability to metastasize to other parts of the body. Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. In 2017, it is expected that there will be 134,490 new cases of CRC and 49,190 deaths. CRC is highly treatable when discovered early however metastatic colorectal cancer (mCRC) carries a poor prognosis with only a 5-year survival rate. Fortunately diagnosing CRC has significantly improved in recent years with the introduction of new therapies which are largely based on the stage of the disease, patient medical history and preferences, predictive biomarkers and other factors. Surgery is typically the main treatment in the first line setting however other therapies are needed to effectively treat patients with mCRC to include chemotherapy, targeted therapies, and immunotherapy; both alone and in combination. These options have shown improved efficacy and safety in mCRC and should be integrated into the treatment paradigm. Additionally, treating adverse effects and comorbidities are just as critical to successfully managing the disease, improve patient outcomes and quality of life.

Upon Completion of this activity, participants will be able to:

  • Assess VEGF- and EGFR-targeting agents, immunotherapy and chemotherapy and their current role in treatment strategies for metastatic colorectal cancer (mCRC)

  • Apply latest clinical data and guidelines in selecting therapy for patients with mCRC who have progressed on previous therapy

  • Analyze which factors driving patient segmentation (prognostic and predictive biomarkers, comorbidities, patients’ preference) impact the treatment decision-making process in different clinical scenario across disease progression

  • Implement individualized treatment strategies for patients with mCRC and comorbidities that may affect later lines of therapy

  • Examine the role of molecular biomarkers in selecting appropriate targeted agents for patients with mCRC in the clinical setting

  • Select patients with mCRC for whom a VEGF- or EGFR-targeting agent, immunotherapy or chemotherapy is an appropriate choice for the next step in the management of their cancer

Faculty: Christopher Lieu, MD
Assistant Professor, Division of Medical Oncology
Director, Gastrointestinal Medical Oncology
University of Colorado Denver School of Medicine


Dr. Lieu serves as a consultant to Merck & Co. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Bayer HealthCare Pharmaceuticals, Lilly USA LLC, and Taiho Oncology

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue